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The diffuse (interstitial) lung diseases have attracted an
unprecedented level of interest over the past 5 years. State-
ments from the American Thoracic Society/European Respi-
ratory Society committees on idiopathic pulmonary fibrosis
(IPF), sarcoidosis and the idiopathic interstitial pneumonias,
and from the British Thoracic Society on diffuse parenchymal
lung diseases [1–3] have defined the phenotype of the idio-
pathic interstitial pneumonias more tightly than was previ-
ously the case. Much of the credit for this lies in the
exploitation of high-resolution computed tomography to
provide a three-dimensional anatomical display, with great
precision, of the patterns of abnormality that occur in diffuse
lung diseases [4]. Such precision has reinvigorated a molec-
ular scientific approach, including molecular genetics, to gain
an understanding of disease causation and progression.
With a more precisely defined diffuse lung disease pheno-
type, it is now possible to apply high throughput, moder-
ately fine mapping technologies to define genetic
predisposition to disease and severity of disease. The more
precise phenotype has also stimulated scientists to rethink
concepts of pathogenesis, particularly with regard to IPF,
and to re-explore the relative contributions of inflammation
and fibrogenesis to this disease. This renaissance in scien-
tific interest has stimulated the pharmaceutical industry into
an unprecedented level of activity with regard to these dis-
eases, with investment in phase II and phase III studies of
novel therapeutic approaches in an attempt to improve the
appalling outcome for the most lethal of the diffuse lung
diseases – IPF. At least seven studies of IPF therapy have
been completed, are proceeding or are at the planning
stages. In this series of articles in volume 3 of Respiratory
Research, we address a number of key areas of develop-
ment, with a specific focus on genetic predisposition and
the fibrogenesis versus inflammation debate in IPF.
Iannuzzi et al. [5] discuss the power of genetic polymor-
phism analysis. They stress the number of pitfalls that can
be encountered and the need for careful study design,
using clearly defined populations, appropriate controls
and a judicious combination of family-based association
studies (generally using genome marker strategies) with
case–control candidate gene studies. With this approach,
important strides can be taken in our understanding of a
variety of lung diseases, particularly chronic beryllium
disease, sarcoidosis and IPF.
Seitzer et al. [6] and Pantelidis et al. [7] provide reviews of
specific genetic targets. Seitzer et al. [6] discuss the loci
on the short arm of chromosome 6, most specifically the
class II human leucocyte antigen (HLA)-DR and tumour
necrosis factor (TNF) loci, and the concept of a complex
haplotype of major histocompatibility complex alleles with
TNF-α and lymphotoxin-α genes. Defining genotype not
just in terms of polymorphisms at one region (in this
instance HLA-DR) but also in terms of those at a second
region (specifically TNF-α in that review) provides evi-
dence that this co-association of polymorphisms at differ-
ent regions of the genome is important in identifying both
disease susceptibility and progression markers. In this
regard, a co-association of HLA-DR3 with TNF-A2 is asso-
ciated with the less severe form of sarcoidosis – Löfgren’s
syndrome [8]. Seitzer et al. conclude that it was difficult to
determine whether the TNF or the HLA-DR allele (which
are in linkage disequilibrium) confers the greater risk, and
that other element(s) in linkage disequilibrium are more
likely to convey susceptibility.
Pantelidis et al. [7] review surfactant polymorphisms in the
light of the recent observation by Nogee et al. [9] of a
polymorphism in the surfactant protein C gene that
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occurred in a mother and daughter, both of whom suffered
from (different) diffuse lung diseases. The importance of
surfactant in normal lung homeostasis and the association
with abnormalities in surfactant in diffuse lung diseases is
outlined. These abnormalities are most typically found in
IPF, but also in sarcoidosis and hypersensitivity pneumoni-
tis. Pantelidis et al. point out that a number of mutations
have now been identified in association with hereditary
surfactant deficiencies, and that all surfactant protein
genes are polymorphic, but associations with diffuse lung
disease have only been described for surfactant protein C
thus far. Since the report by Nogee et al. [9] was pub-
lished, a further series of surfactant protein C mutations
have been identified in 34 infants with non-familial chronic
lung disease (presented at the Thomas L Petty Aspen
Lung Conference; Aspen, CO, USA; June 6–9 2001).
The application of immunogenetic predisposition to the
diffuse lung diseases is an exciting development, and one
that is matched by the intensity and quality of the debate
surrounding the relative contributions of aberrant wound
repair and inflammation to the pathogenesis of IPF. In a
comprehensive commentary based on a recent review
article by Selman et al. [10], Gauldie et al. [11] explore the
concept that IPF is more due to an abnormal wound
healing response than to inflammation-induced injury. They
conclude (citing evidence from their own work and that of
others) that inflammation may be necessary for the evolu-
tion of IPF, but it is insufficient alone to account for the
histopathological and clinical response observations [12].
They suggest that a modulation of the normal interactions
between alveolar epithelial cells and mesenchymal cells
are critical determinants in the evolving disease process.
This issue is debated further in a comprehensive review by
Selman and Pardo [13]. They present an elegantly logical
argument, the central tenet of which is that damage to or
stimulation of the epithelial cell (by cause or causes
unknown) results in triggering of a mesenchymal response
with a perpetuation of fibrogenesis, the trademark fibro-
blastic focus of which is among the more striking conse-
quences of the interaction. Other factors that are probably
involved in the dysregulation of repair include most notably
those involved in coagulation (the balance between proco-
agulant and anticoagulant effects) and in collagen
turnover (profibrotic and antifibrotic mechanisms).
The importance and interaction of growth factors in the
new paradigm is reviewed by Allen and Spiteri [14]. They
highlight the relative contributions of the key growth
factors and the importance of the emergence and persis-
tence of myofibroblasts, together with regulatory factors
including apoptosis.
Keane and Strieter [15] review the role of the balance of
T-helper-1 and T-helper-2 cytokines and chemokines in
fibrosing lung disease, and emphasize the importance of
the concept of balance in biosystems. They ‘rein back’ the
momentum of conceptualizing IPF as a pure injury/
response disease and highlight a variety of inflammatory
responses that must not be minimized in terms of their role
in modifying the pathogenesis of this disease.
The study of diffuse lung disease is in a golden era of
rapid molecular science advances, which are being inte-
grated into the design of new highly targeted therapeutic
strategies. The reviews in this series illustrate the consid-
erable knowledge that has been acquired over recent
years and signposts future goals and targets. In particular,
an increased understanding of the genetic control of
(aberrant) responses to injury, inflammation and fibrosis,
and the relative contributions made by positive and nega-
tive controls in these processes augers well for future and
rapid advances in diffuse lung disease.
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